February 20, 2018

Chuck Broes Discusses the Value of Precision Hiring

Chuck Broes

Chuck Broes

Chuck Broes draws on over forty years of business acumen to offer a perspective on business philosophies and tactics for the next decade. This piece is part 2 of a series.

When Chuck Broes set about choosing his chief management team at Quantum Immunologics, he undertook the task with surgical precision, rather than mere general direction. To assemble a team equipped with skills that were complementary to the tasks at hand, Chuck Broes utilized an innovative recruiting method. Because Chuck Broes had spent decades building fruitful and cooperative business relationships, he was able to streamline the recruitment process and cut directly to a small pool of professionals best suited to his strategies.

Chuck Broes delved into a broad range of disciplines to bring together a first rate team with a synergy of individualized skills. Some of the skills Chuck Broes sought to bring to the table included cancer treatment, manufacturing and early detection technologies. By cultivating connections and strong relationships between the disciplines, Chuck Broes forged a united contingent of eminent thinkers ready for any business challenge.

During hiring, Chuck Broes insisted on managers with a deep proficiency in business, science, accounting, global markets and manufacturing. This impressive payload of international skills has allowed Chuck Broes and Quantum Immunologics to keep abreast of the rapidly growing and changing world of pharmacology research. To this end, Chuck Broes selectively hired progressive managers with an eye for current issues and future developments.

Long ago, Chuck Broes realized that even the smallest business is part of a global network. Chuck Broes also noted that modern telecommunications technology has irrevocably changed the world’s business climate. From telephones to the latest in wireless Internet technology, decisions and developments are occurring at a significantly faster pace every single year. This makes it more important than ever for Chuck Broes to maintain a sharp, foresighted and nimble team of senior managers.

About Chuck Broes

Chuck Broes is a business and healthcare visionary whose career spans over 45 years in domestic and foreign markets. In the past, Chuck Broes has specialized in the areas of incubation, start-ups, mergers and acquisitions, corporate turn-arounds and roll-ups. Chuck Broes has served in various executive roles including Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.

Chuck Broes began his unique career with Health Industries (Jack LaLanne European Health Spas) from its founding to becoming a national chain of over one hundred locations, then going public and later being sold to a Fortune 500 company. This positioned Chuck Broes to serve in key leadership roles within the healthcare and pharmaceutical industries working with regulatory issues involving the FDA, ISO and CE marking and EDI. Chuck Broes was involved intimately as part of the senior management team at Wellmark Corporation, a pioneer company in healthcare clearinghouse services and ANSI X12 standards, which became a subsidiary of Primark Corporation, a NYSE Company.

Later, Chuck Broes founded EliteCorp International, Inc. and served as its Chief Executive Officer. In that capacity Chuck Broes’ business experience has included the facilitation of public companies, acquisitions, mergers, strategic alliances, IPOs and turnarounds. Associated projects for Chuck Broes have ranged from concept to development and production, including the integration of national data communication networks, facilities management, and healthcare system technologies.

Chuck Broes has served as a member of the Ethics Committee of the Moffitt Cancer Center in Tampa, Florida for fifteen years. In 2008, Chuck Broes turned his full attention to Quantum Immunologics, Inc., which he helped found and where he currently serves as CEO. Chuck Broes leads Quantum Immunologics in the pursuit of the research, development and implementation of new immunotherapy protocols for the treatment of cancer. Chuck Broes has initiated clinical trials that are currently underway and new patents have been filed providing the company with a pipeline for ongoing improvements in cancer treatment.

According to Chuck Broes, Quantum Immunologics was formed for the sole purpose of developing, implementing and distributing new advanced levels of proprietary therapeutic treatments and diagnostic tools. Chuck Broes presents Quantum Immunologics’ mission as fostering the development and support for these and other technologies that are complementary to its current portfolio of patented intellectual properties that are focused on immune diseases and disorders.

To contact Chuck Broes or for more information about Quantum Immunologics please visit: www.quantumimmunologics.com or call 866-213-4594.


Speak Your Mind